DKK1 and osteoporosis: demonstrated a critical role for DKK-1 in the pathogenesis of glucocorticoid (GC)-induced bone loss (39), highlighting its potential as a therapeutic target to reduce the risk of osteoporosis resulting from long-term GC therapy.